Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02864381
Registration number
NCT02864381
Ethics application status
Date submitted
10/08/2016
Date registered
12/08/2016
Date last updated
18/09/2020
Titles & IDs
Public title
Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Query!
Scientific title
A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Query!
Secondary ID [1]
0
0
2016-001402-41
Query!
Secondary ID [2]
0
0
GS-US-296-2013
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Gastric Adenocarcinoma
0
0
Query!
Gastroesophageal Junction Adenocarcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Oesophageal (gullet)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Andecaliximab
Treatment: Drugs - Nivolumab
Experimental: Andecaliximab + Nivolumab - Andecaliximab 800 mg plus nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 34 weeks at the time of the primary efficacy analysis; up to 101 weeks at the time of the safety follow-up analysis).
Active Comparator: Nivolumab - Nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 41 weeks at the time of the primary efficacy analysis; up to 97 weeks at the time of the safety follow-up analysis).
Treatment: Drugs: Andecaliximab
800 mg administered via IV infusion
Treatment: Drugs: Nivolumab
3 mg/kg administered via IV infusion
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [1]
0
0
ORR was defined as the percentage of participants with confirmed overall best response of complete response (CR) or partial response (PR) after starting study drug but before starting any new chemotherapy or radiotherapy as assessed by the investigator according to Response Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Query!
Timepoint [1]
0
0
Up to 41 weeks
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS was defined as the interval in months from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause. The first definitive progressive disease (PD) was defined as the first radiation therapy, the first clinical PD, and the first confirmed imaging PD, whichever came first. Participants without PD or death and participants with PD after starting new anti-cancer therapy are censored at the last tumor assessment date.
Query!
Timepoint [1]
0
0
Andecaliximab + Nivolumab median follow-up time: 7.0 months; Nivolumab median follow-up time: 7.1 months
Query!
Secondary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
OS was defined as the interval from the date of randomization to death from any cause. Surviving participants are censored at the last date known alive.
Query!
Timepoint [2]
0
0
Andecaliximab + Nivolumab median follow-up time: 7.0 months; Nivolumab median follow-up time: 7.0 months
Query!
Secondary outcome [3]
0
0
Duration of Response (DOR)
Query!
Assessment method [3]
0
0
DOR was defined as the interval from the date of the first response (complete or partial response) was achieved to the earlier of the first documentation of definitive disease progression or death from any cause.
Query!
Timepoint [3]
0
0
Andecaliximab + Nivolumab median follow-up time: 7.0 months; Nivolumab median follow-up time: 7.1 months
Query!
Secondary outcome [4]
0
0
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Query!
Assessment method [4]
0
0
An adverse event (AE) is any untoward medical occurrence in a clinical study participants administered a medicinal product, which does not necessarily have a causal relationship with the treatment. TEAEs are events that are defined as AEs with onset dates on or after the first dose of andecaliximab/nivolumab and up to 30 days after permanent discontinuation of andecaliximab or 5 months after permanent discontinuation of nivolumab, or led to premature discontinuation of andecaliximab or nivolumab.
Query!
Timepoint [4]
0
0
Andecaliximab: First dose date up to last dose (maximum: 101 weeks) + 30 days; Nivolumab: First dose date up to last dose (maximum: 101 weeks) + 5 months
Query!
Secondary outcome [5]
0
0
Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
Query!
Assessment method [5]
0
0
Treatment-emergent (Chemistry, Hematology, Coagulation, and Urinalysis) laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of the last dose of andecaliximab plus 30 days or nivolumab plus 5 months. If the relevant baseline laboratory value is missing, any abnormality of at least Grade 1 observed within the time frame specified above will be considered treatment-emergent. Percentage of participants with any postbaseline Grade 1 or higher laboratory abnormality is reported.
Query!
Timepoint [5]
0
0
Andecaliximab: First dose date up to last dose (maximum: 101 weeks) + 30 days; Nivolumab: First dose date up to last dose (maximum: 101 weeks) + 5 months
Query!
Eligibility
Key inclusion criteria
Key
- Histologically confirmed inoperable locally advanced or metastatic adenocarcinoma of
the stomach or GEJ which have progressed on at least 1 prior systemic therapy or line
of treatment for unresectable/metastatic disease
- Eastern Cooperative Oncology Group (ECOG) performance score of = 1
- Measurable disease according to Response Criteria in Solid Tumors (RECIST) v1.1
- Tumor sites that can be accessed for repeat biopsies
- Archival tumor tissue, preferably obtained from the most recent available biopsy;
there must be adequate tissue for a Cochran-Mantel Haenszel (CMH) test stratified by
programmed death ligand 1 (PD-L1) stratification test, as assessed by central
pathologist
- Individuals not receiving anticoagulant medication must have an international
normalized ratio (INR) = 1.5 and activated partial thromboplastin (aPTT) = 1.5 x upper
limit of normal (ULN)
- Required baseline laboratory data as outlined in protocol
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Individuals who have received only neoadjuvant or adjuvant therapy for gastric
adenocarcinoma
- Radiotherapy within 28 days of randomization
- Uncontrolled intercurrent illness as outlined in protocol
- History of a concurrent or second malignancy except for those outlined in protocol
- Major surgery, within 28 days of first dose of study drug
- Known positive status for human immunodeficiency virus (HIV)
- Known acute or chronic-active infection with hepatitis B virus (HBV) or hepatitis C
virus (HCV)
- Chronic daily treatment with oral corticosteroids (dose of > 10 mg/day prednisone
equivalent) or other immunosuppressive medications within 14 days of randomization
- Known or suspected central nervous system metastases
- Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6
months of randomization
- Serious systemic fungal, bacterial, viral, or other infection that is not controlled
or requires intravenous antibiotics
- Current or history of pneumonitis or interstitial lung disease
- Active known or suspected autoimmune disease with exceptions noted in protocol.
- History of bone marrow, stem cell, or allogenic organ transplantation
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/08/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
144
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,TAS
Query!
Recruitment hospital [1]
0
0
- Albury
Query!
Recruitment hospital [2]
0
0
- Wahroonga
Query!
Recruitment hospital [3]
0
0
- Douglas
Query!
Recruitment hospital [4]
0
0
- Hobart
Query!
Recruitment postcode(s) [1]
0
0
2640 - Albury
Query!
Recruitment postcode(s) [2]
0
0
2076 - Wahroonga
Query!
Recruitment postcode(s) [3]
0
0
4818 - Douglas
Query!
Recruitment postcode(s) [4]
0
0
7000 - Hobart
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Indiana
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Missouri
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
Belgium
Query!
State/province [6]
0
0
Hainaut
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Oost-Vlaanderen
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Vlaams Brabant
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Finistère
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Marne
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Val-de-Marne
Query!
Country [12]
0
0
Hungary
Query!
State/province [12]
0
0
Budapest
Query!
Country [13]
0
0
Hungary
Query!
State/province [13]
0
0
Debrecen
Query!
Country [14]
0
0
Italy
Query!
State/province [14]
0
0
Forli-Cesena
Query!
Country [15]
0
0
Italy
Query!
State/province [15]
0
0
Ligura
Query!
Country [16]
0
0
Italy
Query!
State/province [16]
0
0
Lombardia
Query!
Country [17]
0
0
Italy
Query!
State/province [17]
0
0
Toscana
Query!
Country [18]
0
0
Poland
Query!
State/province [18]
0
0
Podkarpackie
Query!
Country [19]
0
0
Poland
Query!
State/province [19]
0
0
Poznan
Query!
Country [20]
0
0
Poland
Query!
State/province [20]
0
0
Warszawa
Query!
Country [21]
0
0
Spain
Query!
State/province [21]
0
0
Madrid
Query!
Country [22]
0
0
Spain
Query!
State/province [22]
0
0
Barcelona
Query!
Country [23]
0
0
United Kingdom
Query!
State/province [23]
0
0
Bristol
Query!
Country [24]
0
0
United Kingdom
Query!
State/province [24]
0
0
Edgbaston
Query!
Country [25]
0
0
United Kingdom
Query!
State/province [25]
0
0
London
Query!
Country [26]
0
0
United Kingdom
Query!
State/province [26]
0
0
Manchester
Query!
Country [27]
0
0
United Kingdom
Query!
State/province [27]
0
0
Sutton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Gilead Sciences
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to evaluate and compare the efficacy of andecaliximab
(GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent
gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02864381
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Gilead Study Director
Query!
Address
0
0
Gilead Sciences
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02864381
Download to PDF